[HTML][HTML] Ultra-low dosage regimen of rituximab in autoimmune blistering skin conditions
M Alaibac - Frontiers in immunology, 2018 - frontiersin.org
Rituximab is a chimeric human-mouse monoclonal anti-CD20 antibody initially developed to
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
[引用][C] Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions
M Alaibac - Frontiers in immunology, 2018 - pubmed.ncbi.nlm.nih.gov
Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions Ultra-Low
Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions Front Immunol …
Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions Front Immunol …
[HTML][HTML] Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions
M Alaibac - Frontiers in Immunology, 2018 - frontiersin.org
Rituximab is a chimeric human-mouse monoclonal anti-CD20 antibody initially developed to
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions
M Alaibac - Autoantibodies, 2019 - books.google.com
Rituximab is a chimeric human-mouse monoclonal anti-CD20 antibody initially developed to
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions.
M Alaibac - Frontiers in Immunology, 2018 - europepmc.org
Rituximab is a chimeric human-mouse monoclonal anti-CD20 antibody initially developed to
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
[引用][C] Ultra-low dosage regimen of Rituximab in autoimmune blistering skin conditions
M Alaibac - FRONTIERS IN IMMUNOLOGY, 2018 - research.unipd.it
Ultra-low dosage regimen of Rituximab in autoimmune blistering skin conditions IRIS IRIS Home
Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie IT Italiano Italiano English English …
Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie IT Italiano Italiano English English …
Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions
M Alaibac - Frontiers in Immunology, 2018 - ncbi.nlm.nih.gov
Rituximab is a chimeric human-mouse monoclonal anti-CD20 antibody initially developed to
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …